PSMA引导放疗用于寡复发前列腺癌患者的临床结局
研究纳入2011至2019年86例经PSMA-PET/CT识别的复发性寡转移前列腺癌患者,对转移灶行影像引导放疗。中位随访26个月后,3年总生存率84%、生化无进展生存率55%,无雄激素剥夺治疗生存期中位13.5个月;同步ADT或放疗超过24次者临床结局更好。
要点
- PSMA-PET/CT可识别寡转移灶并对选定的转移灶行影像引导放疗。
- 放疗后83%的患者出现生化反应,照射转移灶的SUV显著下降。
- 中位随访26个月,3年OS 84%、bPFS 55%,ADT-free生存中位13.5个月。
核心结论
- PSMA引导放疗是寡复发前列腺癌男性有前景的治疗方法,照射野内控制极佳。
- 作者认为需要前瞻性随机试验来确定该方法是否带来生存获益。
研究设计与样本
- 2011年至2019年间,经PSMA-PET/CT识别出86例复发性寡转移前列腺癌患者,并对其转移灶行影像引导放疗。
- 研究对复发部位进行特征描述,并列表分析主要终点总生存、生化无进展生存和无雄激素剥夺治疗生存。
主要发现
- 转移灶中37%为骨转移、48%为盆腔淋巴结转移、15%为盆腔外淋巴结转移。
- PSMA引导放疗后,83%的队列检测到生化反应。
- 照射的转移灶中观察到标准摄取值(SUV)有统计学显著下降。
- 中位随访26个月后,3年总生存率为84%,3年生化无进展生存率为55%。
- 无雄激素剥夺治疗生存的中位时间为13.5个月。
临床怎么用
- 作者认为PSMA引导放疗是寡复发前列腺癌有前景的治疗方法,照射野内控制极佳。
- 作者认为需要前瞻性随机试验来确定该方法是否带来生存获益。
局限性
- 作者指出需要前瞻性随机试验来确定该方法是否带来生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases. MATERIALS AND METHODS: Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated. RESULTS: In total, 37% of the metastases were bone metastases, 48% were pelvic nodal metastases, and 15% were nodal metastases outside of the pelvis. After PSMA-guided radiotherapy, a biochemical response was detected in 83% of the cohort. A statistically significant decrease in the standard uptake value (SUV) was seen in irradiated metastases. After a median follow-up of 26 months, the 3-year OS and bPFS were 84% and 55%, respectively. The median time of ADT-free survival was 13.5 months. A better clinical outcome was observed for patients receiving concomitant ADT or more than 24 fractions of radiation. CONCLUSION: PSMA-guided radiotherapy is a promising therapeutic approach with excellent infield control for men with oligorecurrent prostate carcinoma. However, prospective, randomized trials are necessary to determine if this approach confers a survival advantage.
引用
- Stefan A Koerber, Katharina Sprute, Clemens Kratochwil, et al. Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32405735. doi:10.1007/s00259-020-04777-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。